Banner placeholder


Collatamp®, is a lyophilized collagen implant impregnated with the aminoglycoside antibiotic gentamicin. Collatamp® is indicated for local haemostasis of capillary, parenchymatous and seeping haemorrhages in areas with a high risk of infection.

Collatamp® is implanted during surgery and delivers very high levels of gentamicin locally within the wound, however systemically effective blood or plasma levels are not generally achieved. Collatamp contains renatured type 1 collagen and is available with either bovine (Collatamp® G) or equine (Collatamp® EG) collagen. The collagen within Collatamp® is naturally broken down and resorbed by the bodywithin 1-7 weeks of implantation.

According to the local regulatory approvals, Collatamp® is licensed as either a medical device or as a drug and is available in 3 different presentations: 5 cm x 5 cm; 10 cm x 10 cm and 5 cm x 20 cm depending on the country.

More than 40 clinical studies have been conducted with Collatamp®, including pharmaco-economic studies, across a range of surgeries with high risk of infection and/or where surgical site infection can lead to severe complications, such as:

  • Orthopedics
  • Mixed tissue trauma
  • Cardiac surgery
  • Vascular surgery
  • Rectal extirpation
  • Pilonidal sinus
  • Abdominal surgery
  • Appendectomy

Collatamp® is marketed by EUSA Pharma in over 50 countries in Europe, North America, Africa and the Middle East under the following tradenames: Collatamp® G, Collatamp® EG, Sulmycin®Implant, Garamycin® Schwamm, Duracoll®, Garacoll®, Garacol®, Gentacoll®, Gentacol® and Cronocol®.